Citations

Showing 10 of 108081 citations.

Expert perspectives for the pharmacist on facilitating and improving the use of albumin in cirrhosis
Kugelmas, Marcelo , Loftus, Michelle, Owen, Emily , Wadei, Hani M. , Saab, Sammy , Wadei, Hani, Wadei, Hani M

Mayo Clinic

American Journal of Health-System Pharmacy | April 4, 2023 | Volume: 80 | Issue: 13 | Pages: 806-817

10.1093/ajhp/zxad070 | PMID 37013893 Get It

Abstract Purpose Albumin, the most abundant and arguably most important protein in the human body, plays a unique role in decompensated cirrhosis because its structure and function are quantitatively and qualitatively affected. A literature review was performed to provide insights into albumin use. The manuscript was developed using a multidisciplinary approach; 2 hepatologists, a nephrologist, a hospitalist, and a pharmacist, who are all members of or work closely with the Chronic Liver Disease Foundation, collaborated to write this expert perspective review. Summary Cirrhosis represents the potential end in the spectrum of all chronic liver diseases. Decompensated cirrhosis, defined by the overt manifestation of liver failure (eg, ascites, hepatic encephalopathy, variceal bleeding), is the inflection point associated with increased mortality. Human serum albumin (HSA) infusion serves an important role in the treatment of advanced liver disease. The benefits of HSA administration in patients with cirrhosis are widely accepted, and its use has been advocated by several professional societies. However, inappropriate HSA use can lead to significant adverse patient events. This paper discusses the rationale for the administration of HSA in the treatment of complications of cirrhosis, analyzes the data on the use of HSA in cirrhosis, and streamlines practical recommendations set forth in published guidance. Conclusion Use of HSA in clinical practice needs to be improved. The objective of this paper is to empower pharmacists to facilitate and improve the use of HSA in patients with cirrhosis at their practice sites.
A novel application of finite Gaussian mixture model (GMM) using real and simulated biomarkers of cardiovascular disease to distinguish adolescents with and without obesity
Hossain, Jobayer , Balagopal, Prabhakaran

Mayo Clinic

Communications in Statistics: Case Studies, Data Analysis and Applications | April 4, 2023 | Volume: 9 | Issue: 1 | Pages: 106-120

10.1080/23737484.2023.2194249 Get It

MicroRNAs as a therapeutic target in IgA nephropathy in Indian population
Tripathy, Anindita, Poornachandra, Yedla , Vishnubhotla, Ravikanth, Sekaran, Anuradha , Reddy, Sai Keithi, Keithi Reddy, Sai Ram

Mayo Clinic

Biomedical Reports | April 4, 2023 | Volume: 18 | Issue: 5 | Pages: No page available

10.3892/br.2023.1617 | PMID 37089577 Get It

Barriers to head and neck cancer care in high-income and low- and middle-income countries: a scoping review
Sprow, Holly N. , Heer, Baveena, Jashek‐Ahmed, Farizeh , Wiedermann, Joshua P. , Seguya, Amina , Wiedermann, Joshua , Nuss, Sarah

Mayo Clinic

Current Opinion in Otolaryngology & Head & Neck Surgery | April 4, 2023 | Volume: 31 | Issue: 3 | Pages: 185-193

10.1097/moo.0000000000000889 | PMID 37014803 Get It

Purpose of review Identify patient-perceived barriers to head and neck cancer care and compare differences in barriers by country income status. Recent Findings Of the 37 articles, 51% (n = 19) were from low- and middle-income countries (LMICs), while 49% (n = 18) were from high-income countries. Of the papers from high-income countries, unspecified head and neck cancer (HNC) subtype (67%, n = 12) were the most common cancer type, while upper aerodigestive tract mucosal malignancies (58%, n = 11) were more common in LMICs (P = 0.02). Based on World Health Organization barriers, level of education (P = < 0.01) and alternative medicine use (P = 0.04) were greater barriers in LMICs compared to high-income countries. At least 50% of articles listed barriers at all three ‘Three Delays’ timepoints. There were no significant differences by country income status for the ‘Three Delays’ timepoints of deciding to seek care (P = 0.23), reaching the healthcare facility (P = 0.75), or receiving care (P = 1.00). Summary Patients face barriers to care for head and neck cancer regardless of country income status. There is overlap in several barriers and a need for systemic improvement in access. The differences in education and alternative medicine may guide region-specific interventions to improve the provision of head and neck services.
Geographic and Demographic Disparities in Colorectal Cancer: A National Cancer Database Analysis
Mohammed, Turab , Gosain, Rohit , Rana, Navpreet, Lemini, Riccardo , Wang, Katy, Agha, A., Neupane, Arun , Nurkin, Steven, Gabriel, Emmanuel , Boland, Patrick M.

Mayo Clinic

Hematology/Oncology and Stem Cell Therapy | April 4, 2023 | Volume: 16 | Issue: 3 | Pages: 262-271

10.56875/2589-0646.1061 | PMID 37023221 Get It

Background and objectives: Area of residence may adversely affect survival and outcomes in many cancers. The objective of this study was to evaluate the impact of geographical and demographic disparities on survival of patients with colorectal cancer. Materials and methods: Data were obtained from the National Cancer Database (NCDB) colon, rectosigmoid, and rectal datasets. Patients were categorized by area of residence, namely, metropolitan (MA), urban (UA), or rural (RA). Sociodemographic and tumor-related data were collected and analyzed to evaluate variables affecting overall survival (OS). Results: In total, 973,139 patients between 2004 and 2013 were included in the study, of which 83%, 15%, and 2% were MA, UA, and RA residents, respectively. RA and UA patients were mostly white male with low income and no comorbidities. In univariate analysis, OS was worse for RA (hazard ratio [HR] 1.10) and UA (HR 1.06) colorectal cancer patients than that for MA colorectal cancer patients. In multivariate analysis revealed significant association between OS and geographic residence, with worse OS for RA (HR 1.02, p = 0.04) and UA (HR 1.01, p = 0.003) patients. Black (HR 1.14) and Native American (HR 1.17) patients had worse outcomes, while Asians (HR 0.8), women (HR 0.88), and patients with higher income had improved OS (HR 0.88). Conclusion: The differences in the OS for RA and UA patients with colorectal cancer were significantly driven by economic disparity. Area of residence represents an important factor independently limiting access to care, particularly in geographically isolated individuals.
Myocardial Inflammation as a Manifestation of Genetic Cardiomyopathies: From Bedside to the Bench
Peretto, Giovanni , Resta, Chiara Di , Rabino, Martina , Villatore, Andrea , Lazzeroni, Davide , Sala, Simone , Cooper, Leslie T. , Di Resta, Chiara , Villatore, Andrea , Lazzeroni, Davide , Sala, Simone , Cooper, Leslie T , Sommariva, Elena , Pompilio, Giulio

Mayo Clinic

Biomolecules | April 4, 2023 | Volume: 13 | Issue: 4 | Pages: 646

10.3390/biom13040646 | PMID 37189393 Get It

Over recent years, preclinical and clinical evidence has implicated myocardial inflammation (M-Infl) in the pathophysiology and phenotypes of traditionally genetic cardiomyopathies. M-Infl resembling myocarditis on imaging and histology occurs frequently as a clinical manifestation of classically genetic cardiac diseases, including dilated and arrhythmogenic cardiomyopathy. The emerging role of M-Infl in disease pathophysiology is leading to the identification of druggable targets for molecular treatment of the inflammatory process and a new paradigm in the field of cardiomyopathies. Cardiomyopathies constitute a leading cause of heart failure and arrhythmic sudden death in the young population. The aim of this review is to present, from bedside to bench, the current state of the art about the genetic basis of M-Infl in nonischemic cardiomyopathies of the dilated and arrhythmogenic spectrum in order to prompt future research towards the identification of novel mechanisms and treatment targets, with the ultimate goal of lowering disease morbidity and mortality.
Reassessing Geographic, Logistical, and Cold Ischemia Cutoffs in Liver Transplantation
Ohara, Stephanie, Macdonough, Elizabeth , Morgan, Paige , Das, Devika , Egbert, Lena K. , Brooks, Abigail , Mathur, Amit K. , Aqel, Bashar , Reddy, Kunam S. , Mathur, Amit , Jadlowiec, Caroline , Das, Devika , Lizaola‐Mayo, Blanca , Morgan, Paige, Aqel, Bashar A. , Jadlowiec, Caroline C.

Mayo Clinic

Progress in Transplantation | April 4, 2023 | Volume: 33 | Issue: 2 | Pages: 168-174

10.1177/15269248231164169 | PMID 37013356 Get It

Introduction Liver acceptance patterns vary significantly between transplant centers. Data pertaining to outcomes of livers declined by local and regional centers and allocated nationally remains limited. Project aim The objective was to compare post-liver transplant outcomes between liver allografts transplanted as a result of national and local-regional allocation. Design This was a retrospective evaluation of 109 nationally allocated liver allografts used for transplant by a single center. Outcomes of nationally allocated grafts were compared to standard allocation grafts (N = 505) during the same period. Results Recipients of nationally allocated grafts had lower model for end stage liver disease scores (17 vs 22, P = .001). Nationally allocated grafts were more likely to be post-cross clamp offers (29.4% vs 13.4%, P = .001) and have longer cold ischemia times (median hours 7.8 vs 5.5, P = .001). Early allograft dysfunction was common (54.1% vs 52.5%, P = .75) and did not impact hospital length of stay (median 5 vs 6 days, P = .89). There were no differences in biliary complications ( P = .11). There were no differences in patient ( P = .88) or graft survival ( P = .35). In a multivariate model, after accounting for differences in cold ischemia time and posttransplant biliary complications, nationally allocated grafts were not associated with increased risk for graft loss (HR 0.9, 95% CI 0.4-1.8). Abnormal liver biopsy findings (33.0%) followed by donor donation after circulatory death status (22.9%) were the most common reasons for decline by local-regional centers. Conclusion Despite longer cold ischemia times, patient and graft survival outcomes remain excellent and comparable to those seen from standard allocation grafts.
The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
Neth, Bryan J. , Webb, Mason , Sener, Uğur , Webb, Mason James , Sener, Ugur , Neth, Byran J. , Parney, Ian F.

Mayo Clinic

Pharmaceutics | April 4, 2023 | Volume: 15 | Issue: 4 | Pages: 1134

10.3390/pharmaceutics15041134 | PMID 37111620 Get It

Glioblastoma (GBM) is the most common malignant primary brain tumor and confers a dismal prognosis. With only two FDA-approved therapeutics showing modest survival gains since 2005, there is a great need for the development of other disease-targeted therapies. Due, in part, to the profound immunosuppressive microenvironment seen in GBMs, there has been a broad interest in immunotherapy. In both GBMs and other cancers, therapeutic vaccines have generally yielded limited efficacy, despite their theoretical basis. However, recent results from the DCVax-L trial provide some promise for vaccine therapy in GBMs. There is also the potential that future combination therapies with vaccines and adjuvant immunomodulating agents may greatly enhance antitumor immune responses. Clinicians must remain open to novel therapeutic strategies, such as vaccinations, and carefully await the results of ongoing and future trials. In this review of GBM management, the promise and challenges of immunotherapy with a focus on therapeutic vaccinations are discussed. Additionally, adjuvant therapies, logistical considerations, and future directions are discussed.
Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis
Driver, Christine , D’Souza, Ryan S. , Driver, C Noelle, D'Souza, Ryan S , Driver, C. Noelle

Mayo Clinic

Biomedicines | April 4, 2023 | Volume: 11 | Issue: 4 | Pages: 1087

10.3390/biomedicines11041087 | PMID 37189705 Get It

Current pharmacologic treatments may provide limited analgesia in fibromyalgia and other chronic pain disorders. Low-dose naltrexone (LDN) has emerged as a potential analgesic option that has been minimally explored. This study aims to describe current real-world prescribing practices of LDN, to investigate if patients have a perceived benefit of LDN in treating pain symptoms and to identify predictors associated with a perceived benefit or discontinuation of LDN. We evaluated all outpatient prescriptions for LDN prescribed for any pain indication in the Mayo Clinic Enterprise from 1 January 2009 to 10 September 2022. A total of 115 patients were included in the final analysis. The patients were 86% female, had a mean age of 48 ± 16 years, and 61% of prescriptions were for fibromyalgia-related pain. The final daily dose of oral LDN ranged from 0.8 to 9.0 mg, while the most common dose was 4.5 mg once daily. Of patients who reported follow-up data, 65% reported benefit in their pain symptoms while taking LDN. Adverse effects were reported in 11 (11%) patients and 36% discontinued taking LDN by the most recent follow-up. Concomitant analgesic medications were used by 60% of patients and were not associated with perceived benefit nor discontinuation of LDN, including concomitant opioids. LDN is a relatively safe pharmacologic option that may benefit patients with chronic pain conditions and warrants further investigation in a prospective, controlled, and well-powered randomized clinical trial.
Gait Apraxia and Hakim’s Disease: A Historical Review
Milletti, David , Randi, Filippo Tamburini , Hakim, Fernando, Palandri, Giorgio , Palandri, Giorgio , Lanzino, Giuseppe

Mayo Clinic

Biomedicines | April 4, 2023 | Volume: 11 | Issue: 4 | Pages: 1086

10.3390/biomedicines11041086 | PMID 37189704 Get It

In 1965, Prof. Salomón Hakim described, for the first time, a condition characterized by normal pressure hydrocephalus and gait alterations. During the following decades, definitions such as “Frontal Gait”, “Bruns’ Ataxia” and “Gait Apraxia” have been frequently used in pertinent literature in the attempt to best define this peculiar motor disturbance. More recently, gait analysis has further shed light on the typical spatiotemporal gait alterations that characterize this neurological condition, but a clear and shared definition of this motor condition is still lacking. In this historical review, we described the origins of the terms “Gait Apraxia”, “Frontal Gait” and “Bruns’ Ataxia”, starting with the first works of Carl Maria Finkelburg, Fritsch and Hitzig and Steinthal during the second half of the 19th century and ending with Hakim’s studies and his formal definition of idiopathic normal pressure hydrocephalus (iNPH). In the second part of the review, we analyze how and why these definitions of gait have been associated with Hakim’s disease in the literature from 1965 to the present day. The definition of “Gait and Postural Transition Apraxia” is then proposed, but fundamental questions about the nature and mechanisms underlying this condition remain unanswered.